Galecto (GLTO) Stock Forecast, Price Target & Predictions
GLTO Stock Forecast
Galecto stock forecast is as follows: an average price target of $10.00 (represents a 69.49% upside from GLTO’s last price of $5.90) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
GLTO Price Target
The average price target for Galecto (GLTO) is $10.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 69.49% upside from GLTO's last price of $5.90.
GLTO Analyst Ratings
According to 1 Wall Street analysts, Galecto's rating consensus is 'Buy'. The analyst rating breakdown for GLTO stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Galecto Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 17, 2024 | Jay Olson | Oppenheimer | $10.00 | $6.71 | 49.03% | 69.49% |
The latest Galecto stock forecast, released on Oct 17, 2024 by Jay Olson from Oppenheimer, set a price target of $10.00, which represents a 49.03% increase from the stock price at the time of the forecast ($6.71), and a 69.49% increase from GLTO last price ($5.90).
Galecto Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $10.00 | $10.00 |
| Last Closing Price | $5.90 | $5.90 | $5.90 |
| Upside/Downside | -100.00% | 69.49% | 69.49% |
In the current month, the average price target of Galecto stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Galecto's last price of $5.90. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 17, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jun 10, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Galecto's last stock rating was published by Oppenheimer on Oct 17, 2024. The company gave GLTO a "Outperform" rating, the same as its previous rate.
Galecto Financial Forecast
Galecto Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | - |
| Surprise % | - | - | - |
Galecto's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GLTO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Galecto EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict GLTO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Galecto's previous annual EBITDA (undefined) of $NaN.
Galecto Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| Net Income | - | - | - |
| Avg Forecast | $-3.23M | $-4.24M | $-163.64M |
| High Forecast | $-3.23M | $-4.24M | $-163.64M |
| Low Forecast | $-3.23M | $-4.24M | $-163.64M |
| Surprise % | - | - | - |
Galecto's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GLTO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Galecto SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
Galecto's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GLTO last annual SG&A of $NaN (undefined).
Galecto EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EPS | - | - | - |
| Avg Forecast | $-2.82 | $-3.70 | $-6.04 |
| High Forecast | $-2.82 | $-3.70 | $-6.04 |
| Low Forecast | $-2.82 | $-3.70 | $-6.04 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Galecto's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GLTO previous annual EPS of $NaN (undefined).
Galecto Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CHRS | Coherus BioSciences | $0.82 | $9.00 | 997.56% | Hold |
| SPRO | Spero Therapeutics | $1.16 | $10.00 | 762.07% | Buy |
| LYEL | Lyell Immunopharma | $1.11 | $6.67 | 500.90% | Hold |
| MOLN | Molecular Partners | $5.46 | $29.00 | 431.14% | Buy |
| ACRV | Acrivon Therapeutics | $6.38 | $21.83 | 242.16% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.39 | $7.00 | 192.89% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.52 | $38.80 | 186.98% | Buy |
| TERN | Terns Pharmaceuticals | $5.91 | $14.25 | 141.12% | Buy |
| CGEM | Cullinan Oncology | $13.10 | $31.50 | 140.46% | Buy |
| BOLT | Bolt Biotherapeutics | $0.56 | $1.00 | 78.57% | Hold |
| GLTO | Galecto | $5.90 | $10.00 | 69.49% | Buy |
| MLTX | MoonLake Immunotherapeutics | $49.33 | $79.33 | 60.81% | Buy |
| EWTX | Edgewise Therapeutics | $31.51 | $45.00 | 42.81% | Buy |
| CNTA | Centessa Pharmaceuticals | $16.83 | $23.25 | 38.15% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.22 | $6.67 | 27.78% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $56.47 | $60.63 | 7.37% | Buy |
| AADI | Aadi Bioscience | $2.21 | $1.63 | -26.24% | Hold |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
| ALGS | Aligos Therapeutics | $18.50 | $3.00 | -83.78% | Hold |